## Nathalie Vernaz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3052066/publications.pdf

Version: 2024-02-01

44 papers

1,582 citations

471371 17 h-index 38 g-index

44 all docs

44 docs citations

44 times ranked 1882 citing authors

#	Article	IF	CITATIONS
1	Universal Screening for Methicillin-Resistant <emph type="ital">Staphylococcus aureus</emph> at Hospital Admission and Nosocomial Infection in Surgical Patients. JAMA - Journal of the American Medical Association, 2008, 299, 1149.	3.8	483
2	Impact of Combined Low-Level Mupirocin and Genotypic Chlorhexidine Resistance on Persistent Methicillin-Resistant Staphylococcus aureus Carriage After Decolonization Therapy: A Case-control Study. Clinical Infectious Diseases, 2011, 52, 1422-1430.	2.9	163
3	Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. Journal of Antimicrobial Chemotherapy, 2008, 62, 601-607.	1.3	140
4	The impact of antibiotic use on the incidence and resistance pattern of extendedâ€spectrum betaâ€lactamaseâ€producing bacteria in primary and secondary healthcare settings. British Journal of Clinical Pharmacology, 2012, 74, 171-179.	1.1	87
5	Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. Journal of Antimicrobial Chemotherapy, 2011, 66, 928-935.	1.3	77
6	Dynamics of active pharmaceutical ingredients loads in a Swiss university hospital wastewaters and prediction of the related environmental risk for the aquatic ecosystems. Science of the Total Environment, 2016, 547, 244-253.	3.9	68
7	NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Reports, 2021, 3, 100231.	2.6	54
8	Multihospital Outbreak of <i>Clostridium difficile </i> Ribotype 027 Infection: Epidemiology and Analysis of Control Measures. Infection Control and Hospital Epidemiology, 2011, 32, 210-219.	1.0	52
9	Quasiexperimental Study of the Effects of Antibiotic Use, Gastric Acid-Suppressive Agents, and Infection Control Practices on the Incidence of Clostridium difficile -Associated Diarrhea in Hospitalized Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 2082-2088.	1.4	46
10	Temporal Variability of Antibiotics Fluxes in Wastewater and Contribution from Hospitals. PLoS ONE, 2013, 8, e53592.	1.1	46
11	Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents. Journal of Environmental Management, 2015, 160, 324-332.	3.8	40
12	Temporal effects of antibiotic use and Clostridium difficile infections. Journal of Antimicrobial Chemotherapy, 2009, 63, 1272-1275.	1.3	38
13	Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis. PLoS Medicine, 2013, 10, e1001460.	3.9	33
14	Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic. Preventive Medicine, 2021, 150, 106696.	1.6	27
15	Staphylococcus aureus and methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. Swiss Medical Weekly, 2016, 146, w14339.	0.8	26
16	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics Journal, 2019, 19, 211-218.	0.9	25
17	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines, 2021, 9, 372.	2.1	22
18	Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. Swiss Medical Weekly, 2020, 150, w20446.	0.8	21

#	Article	IF	Citations
19	Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. Lancet Psychiatry, the, 2014, 1, 55-62.	3.7	17
20	Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098.	1.1	16
21	Integrated stochastic modeling of pharmaceuticals in sewage networks. Stochastic Environmental Research and Risk Assessment, 2016, 30, 1087-1097.	1.9	13
22	Gender gap in medical research: a bibliometric study in Swiss university hospitals. Scientometrics, 2021, 126, 741-755.	1.6	12
23	Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. JHEP Reports, 2021, 3, 100279.	2.6	12
24	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Medical Mycology, 2021, 59, 701-711.	0.3	8
25	Determination of antiretroviral drugs for buyers' club in Switzerland using capillary electrophoresis methods. Electrophoresis, 2021, 42, 708-718.	1.3	7
26	Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study. BMJ Open, 2021, 11, e044242.	0.8	7
27	How to Develop and Implement a Computerized Decision Support System Integrated for Antimicrobial Stewardship? Experiences From Two Swiss Hospital Systems. Frontiers in Digital Health, 2020, 2, 583390.	1.5	6
28	A buyers' club to improve access to hepatitis C treatment for vulnerable populations. Swiss Medical Weekly, 2018, 148, w14649.	0.8	6
29	Accuracy of PubMed-based author lists of publications and use of author identifiers to address author name ambiguity: a cross-sectional study. Scientometrics, 2021, 126, 4121-4135.	1.6	5
30	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
31	Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. Mycopathologia, 2021, 186, 775-788.	1.3	5
32	Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines. Pharmacology Research and Perspectives, 2016, 4, e00234.	1.1	3
33	Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals. PLoS ONE, 2019, 14, e0223649.	1.1	3
34	The Swiss Cheese Prescribing Model for Precision Medicine. American Journal of Medicine, 2020, 133, 1249-1251.	0.6	3
35	SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees. PLoS ONE, 2021, 16, e0250021.	1.1	3
36	Prioritization of Active Pharmaceutical Ingredients in Hospital Wastewater. Handbook of Environmental Chemistry, 2017, , 49-69.	0.2	1

#	Article	IF	CITATIONS
37	Scientific publications in internal medicine and family medicine: a comparative cross-sectional study in Swiss university hospitals. Family Practice, 2020, 38, 299-305.	0.8	1
38	Bacteremia Detection in Second or Subsequent Blood Cultures Among Hospitalized Patients in a Tertiary Care Hospital. JAMA Network Open, 2022, 5, e228065.	2.8	1
39	Hepatitis C virus screening of people with severe mental illness: a cost-effectiveness analysis. Journal of Hepatology, 2020, 73, S818-S819.	1.8	O
40	Impact of restricting procalcitonin measurements in a Swiss tertiary-care hospital on antibiotic use, clinical outcomes, and costs: An interrupted time-series analysis. Infection Control and Hospital Epidemiology, 2021, 42, 890-892.	1.0	0
41	Title is missing!. , 2019, 14, e0223649.		0
42	Title is missing!. , 2019, 14, e0223649.		0
43	Title is missing!. , 2019, 14, e0223649.		O
44	Title is missing!. , 2019, 14, e0223649.		0